1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/29281
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKarapetis C.S.en
dc.contributor.authorPrice T.J.en
dc.contributor.authorSegelov E.en
dc.contributor.authorTebbutt N.C.en
dc.contributor.authorLau D.K.en
dc.contributor.authorBurge M.en
dc.contributor.authorRoy A.en
dc.contributor.authorChau I.en
dc.contributor.authorHaller D.G.en
dc.contributor.authorShapiro J.D.en
dc.contributor.authorPeeters M.en
dc.contributor.authorPavlakis N.en
dc.date.accessioned2021-05-14T09:53:24Zen
dc.date.available2021-05-14T09:53:24Zen
dc.date.copyright2020en
dc.date.created20200502en
dc.date.issued2020-05-02en
dc.identifier.citationExpert Review of Anticancer Therapy. 20 (4) (pp 251-270), 2020. Date of Publication: 02 Apr 2020.en
dc.identifier.issn1473-7140en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/29281en
dc.description.abstractIntroduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behavior according to molecular subtype. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarizes expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping. Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-type profiles, with evidence that they should be further restricted to patients with left-sided tumors. Clinically distinct treatment pathways based on tumor RAS, BRAF, HER2 and MMR status, are now clinically applicable. Evidence suggests therapy for additional subgroups will soon be defined; the most advanced being for patients with KRAS G12 C mutation and gene TRK fusion defects.Copyright © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.en
dc.languageenen
dc.languageEnglishen
dc.publisherTaylor and Francis Ltden
dc.relation.ispartofExpert Review of Anticancer Therapyen
dc.subject.meshencorafenib-
dc.subject.mesherlotinib-
dc.subject.meshfluoropyrimidine-
dc.subject.meshfluorouracil-
dc.subject.meshfolinic acid-
dc.subject.meshgimeracil plus oteracil potassium plus tegafur-
dc.subject.meshirinotecan-
dc.subject.meshmitomycin-
dc.subject.meshoxaliplatin-
dc.subject.meshpanitumumab-
dc.subject.meshramucirumab-
dc.subject.meshtipiracil plus trifluridine-
dc.subject.meshtrametinib-
dc.subject.meshBRAF gene-
dc.subject.meshHER2 gene-
dc.subject.meshKRAS gene-
dc.subject.meshNTRK gene-
dc.subject.meshmrtx 849-
dc.subject.meshvemurafenib-
dc.subject.meshcancer chemotherapy-
dc.subject.meshdiarrhea-
dc.subject.meshevidence based medicine-
dc.subject.meshfebrile neutropenia-
dc.subject.meshgene-
dc.subject.meshgene amplification-
dc.subject.meshgene expression-
dc.subject.meshgene mutation-
dc.subject.meshmedical expert-
dc.subject.meshmedical specialist-
dc.subject.meshmetastatic colorectal cancer-
dc.subject.meshmicrobiome-
dc.subject.meshmismatch repair-
dc.subject.meshneutropenia-
dc.subject.meshsignal transduction-
dc.subject.meshaflibercept-
dc.subject.meshbevacizumab-
dc.subject.meshcapecitabine-
dc.subject.meshcetuximab-
dc.subject.meshcirculating tumor DNA-
dc.subject.meshdabrafenib-
dc.titleUpdate on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.en
dc.typeReviewen
dc.identifier.affiliationOncology-
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/14737140.2020.1744439-
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid32186929 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32186929]en
dc.identifier.source2004594345en
dc.identifier.institution(Lau, Chau) GI and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom (Burge) Medical Oncology, Royal Brisbane Hospital, Brisbane, Australia (Burge) University of Queensland, Brisbane, Australia (Roy) Medical Oncology, Flinders Centre for Innovation in Cancer, Bedford Park, Australia (Haller) Abramson Cancer Center at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States (Shapiro, Segelov) Monash University, Melbourne, Australia (Shapiro) Medical Oncology, Cabrini Medical Centre, Melbourne, Australia (Peeters) Medical Oncology, University Hospital Antwerp, Edegem, Belgium (Pavlakis) Medical Oncology, Royal North Shore Hospital, St Leonards, Australia (Pavlakis) Sydney University, Camperdown, Sydney, Australia (Karapetis) Medical Oncology, Flinders Medical Centre, Bedford Park, Australia (Tebbutt) Medical Oncology, Austin Health, Heidelberg, Australia (Tebbutt) Department of Surgery, University of Melbourne, Melbourne, Australia (Segelov) Medical Oncology, Monash Medical Centre, Clayton, Australia (Price) Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australiaen
dc.description.addressT.J. Price, Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia. E-mail: timothy.price@health.sa.gov.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2020 Elsevier B.V., All rights reserved.en
dc.subect.keywordsBRAF chemotherapy Colorectal consensus metastatic MSI RASen
dc.identifier.authoremailPrice T.J.; timothy.price@health.sa.gov.auen
dc.description.grantOrganization: *Beijing Institute of Technology Research Fund Program for Young Scholars* Organization No: 501100012236 Country: Chinaen
item.fulltextNo Fulltext-
item.openairetypeReview-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptOncology-
Appears in Collections:Articles
Show simple item record

Page view(s)

24
checked on Oct 26, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.